NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX and ThyraMir molecular thyroid tests have received coverage from four additional Blue Cross Blue Shield plans.
The ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier are used to diagnose thyroid nodules with indeterminate cytology. According to Interpace, both tests are now covered by Blue Cross Blue Shield of Arizona, Blue Cross Blue Shield of South Carolina, Wellmark Blue Cross Blue Shield of Iowa, and Wellmark Blue Cross Blue Shield of South Dakota. The four payors represent more than 5 million members combined.
"The coverage of ThyGenX and ThyraMir by these additional Blue Cross Blue Shield plans is further evidence that we have met the clinical utility threshold required to secure reimbursement for these tests," Interpace President and CEO Jack Stover said in a statement.
Interpace said that its thyroid tests are now covered for over 280 million patients nationwide, including through Medicare, Medicare Advantage, and national and regional health plans.